A recent study of Wasenang et al. revealed that cfDNA methylation of OPCML (opioid binding protein/cell adhesion molecule-like) and HOXD9 (homeobox D9) could serve as a differential biomarker for cholangiocarcinoma and other biliary diseases [130]. This evidence concerns the gene OPCML and cholangiocarcinoma.